KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Assets (2020 - 2026)

AbCellera Biologics filings provide 7 years of Assets readings, the most recent being $1.3 billion for Q1 2026.

  • Quarterly Assets fell 2.76% to $1.3 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.3 billion through Mar 2026, down 2.76% year-over-year, with the annual reading at $1.4 billion for FY2025, 0.26% changed from the prior year.
  • Assets hit $1.3 billion in Q1 2026 for AbCellera Biologics, down from $1.4 billion in the prior quarter.
  • Across five years, Assets topped out at $1.6 billion in Q2 2022 and bottomed at $1.3 billion in Q1 2026.
  • Average Assets over 5 years is $1.5 billion, with a median of $1.5 billion recorded in 2024.
  • The largest annual shift saw Assets soared 41.09% in 2022 before it fell 8.57% in 2024.
  • AbCellera Biologics' Assets stood at $1.5 billion in 2022, then dropped by 3.43% to $1.5 billion in 2023, then fell by 8.57% to $1.4 billion in 2024, then fell by 0.26% to $1.4 billion in 2025, then dropped by 3.67% to $1.3 billion in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Assets are $1.3 billion (Q1 2026), $1.4 billion (Q4 2025), and $1.4 billion (Q3 2025).